View Clinical Trial (Medical Research Study)
Repair of Large Abdominal Hernia Defects By A Novel Biologic Mesh: A Prospective Multi-Center Observational Study
| City: |
|
Syracuse |
| State: |
|
New York |
| Zip Code: |
|
13210 |
| Conditions: |
|
Hernia |
| Purpose: |
|
The rate of hernia recurrence at one year following repair of a large abdominal hernia with
a biologic mesh is high, ranging from 30% to 100%, with a reported historic average rate of
40%. The purpose of this study is to evaluate the rate of hernia recurrence at one year
following repair with SurgiMend 3.0, an FDA-cleared novel biologic mesh, the hypothesis
being that such rate will be less than 20% at one year, representing a 50% reduction over
the historic rate of 40%.
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
All three of the following criteria must be present for enrollment into the study:
- Large abdominal hernia
- Inability to close the fascia primarily
- Contra-indication for the use of synthetic mesh
- Age > 18 years
Exclusion Criteria:
- Use of SurgiMend 3.0 to simply reinforce a complete closure of the fascia performed
either primarily or sequentially or by component separation technique
- Inability to close the skin over the SurgiMend 3.0
|
| NCT ID: |
|
NCT00892333 |
| Primary Contact: |
|
Principal Investigator George C Velmahos, MD, Ph.D. Massachusetts General Hospital/ Harvard University
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Syracuse, New York 13210 United States
Moustafa Hassan, M.D. Email: hassanm@upstate.edu
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 18, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|